We are live on ! Find out more

29 hedge funds and large institutions have $11.4M invested in IN8bio in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,794% more capital inflows, than outflows

Capital inflows: $6.87M | Capital outflows: $363K

38% more funds holding

Funds holding: 21 → 29 (+8)

18.99% more ownership

Funds ownership: 7.84% → 26.83% (+19%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
29
Holders Change
+8
Holders Change %
+38.1%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
6
Reduced
6
Closed
–
Calls
$1.13M
Puts
–
Net Calls
+$1.13M
Net Calls Change
+$1.13M

INAB Hedge Fund Activity: Q4 2023 in Review

29 of the 6,878 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q4 2023, worth a combined $11.4M — up 342% from $2.58M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new INAB positions and 0 closed out — a net gain of 8 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $4.37M. The largest seller was Voss Capital, cutting an estimated $182K.

  • 29 institutional investors held IN8bio (INAB) as of Q4 2023, up from 21 in Q3 2023.
  • Funds reported $11.4M of IN8bio stock for Q4 2023, up 342% quarter-over-quarter.
  • 8 funds opened new IN8bio positions in Q4 2023 and 0 closed out, a net change of +8 holders.
  • The largest IN8bio buyer in Q4 2023 was AIGH Capital Management, an estimated $4.37M added.
  • The largest IN8bio seller in Q4 2023 was Voss Capital, an estimated $182K sold.

Based on aggregated 13F filings for Q4 2023.